A pharmaceutical procurement manager is reviewing a supplier's stability data for a new Active Pharmaceutical Ingredients source. The certificate of analysis shows the material meets specification at release. But the accelerated stability study shows a 2.5% degradation after six months at 40°C/75% RH. The specification allows no more than 1.5% degradation. The material is compliant on the day of release, but it will not remain compliant through the product's shelf life. This is the central challenge of sourcing Active Pharmaceutical Ingredients: the material must be stable not just at the moment of delivery, but throughout its storage, formulation, and use. Stability is not a single property. It is the result of a complex interplay of molecular structure, environmental conditions, manufacturing process, and packaging. For buyers, understanding these factors is essential for selecting a supplier and a grade of Active Pharmaceutical Ingredients that will perform reliably.
This guide is written for procurement managers, quality assurance professionals, and formulation scientists who are responsible for sourcing Active Pharmaceutical Ingredients. We will examine the intrinsic factors that determine a molecule's stability, the extrinsic factors that accelerate degradation, the manufacturing and packaging decisions that affect stability, and the criteria for evaluating a supplier's stability data. We will also provide detailed product parameters from our factory at Henan Purui Pharmaceutical Co., Ltd. Whether you are sourcing a new API for a generic formulation, evaluating a second source for an existing product, or investigating a stability failure, this guide will help you understand the factors that matter and how to address them.
The stability of an Active Pharmaceutical Ingredients is first determined by its molecular structure. Certain functional groups are inherently reactive and susceptible to degradation pathways. The most common degradation pathways are hydrolysis, oxidation, photolysis, and isomerization. Hydrolysis occurs when a molecule reacts with water, typically at an ester, amide, or lactam bond. Oxidation occurs when a molecule loses electrons, often at a double bond, an aromatic ring, or a heteroatom. Photolysis occurs when a molecule absorbs light energy and undergoes a chemical change. Isomerization occurs when a molecule rearranges its atoms to form a different isomer. The table below summarizes these degradation pathways and the functional groups that are most susceptible.
| Degradation Pathway | Susceptible Functional Groups | Typical Stabilization Strategy |
| Hydrolysis | Esters, amides, lactams | Control moisture, adjust pH, use non-aqueous formulation |
| Oxidation | Double bonds, aromatic rings, heteroatoms | Add antioxidants, use nitrogen blanket, control oxygen |
| Photolysis | Aromatic rings, conjugated systems | Use opaque packaging, add UV absorbers |
| Isomerization | Chiral centers, double bonds | Control temperature, pH, and light |
At Purui, our factory produces Active Pharmaceutical Ingredients with a focus on molecular stability. We characterize the degradation pathways of each product and develop manufacturing processes that minimize the formation of degradation products. We also provide our customers with the intrinsic stability data they need to design a formulation and packaging system that protects the API throughout its shelf life.
Environmental conditions are the second major factor influencing the stability of Active Pharmaceutical Ingredients. The most important conditions are temperature, humidity, light, and oxygen. Temperature accelerates all chemical reactions, including degradation. The Arrhenius equation describes the relationship between temperature and reaction rate: a 10°C increase in temperature typically doubles the reaction rate. Humidity provides the water needed for hydrolysis and can also promote microbial growth. Light provides the energy needed for photolysis. Oxygen provides the reactant needed for oxidation. The table below summarizes the effect of these environmental conditions and the typical control measures.
| Environmental Factor | Effect on API Stability | Control Measure |
| Temperature | Accelerates all degradation reactions | Store at controlled temperature (2-8°C or 15-25°C) |
| Humidity | Promotes hydrolysis, microbial growth | Store in sealed container with desiccant |
| Light | Promotes photolysis | Store in opaque or amber container |
| Oxygen | Promotes oxidation | Blanket with nitrogen, use antioxidant |
| pH | Catalyzes hydrolysis, isomerization | Buffer to optimal pH for stability |
At our factory, we control the environmental conditions during the manufacture and storage of our Active Pharmaceutical Ingredients. We use temperature-controlled warehouses, humidity-controlled production rooms, and nitrogen blanketing for oxidation-sensitive products. We also provide our customers with recommended storage conditions and packaging specifications to ensure that the API remains stable after it leaves our facility.
The manufacturing process can have a significant effect on the stability of Active Pharmaceutical Ingredients. The process determines the crystal form, the particle size, the residual solvents, and the impurity profile. Each of these factors can affect stability. Crystal form is particularly important. Many APIs can exist in different polymorphic forms, and different forms have different physical and chemical stability. The most stable form should be selected for development, and the process must be controlled to ensure that the correct form is produced consistently. Particle size affects the surface area available for degradation reactions. Smaller particles have a larger surface area and may degrade faster. Residual solvents can react with the API or catalyze degradation. The impurity profile affects stability because some impurities can catalyze degradation or be degradation products themselves. The table below summarizes these process-related factors.
| Process Factor | Effect on Stability | Control Strategy |
| Crystal Form | Different polymorphs have different stability | Select the most stable form, control crystallization |
| Particle Size | Smaller particles degrade faster | Control milling and micronization |
| Residual Solvents | Can react or catalyze degradation | Control drying and purification |
| Impurity Profile | Impurities can catalyze degradation | Control purification and isolation |
| Morphology | Affects flow, compaction, and stability | Control crystallization conditions |
At Henan Purui Pharmaceutical Co., Ltd., our factory controls the manufacturing process to ensure the consistent production of stable Active Pharmaceutical Ingredients. We characterize the polymorphic forms of each product, select the most stable form for production, and control the crystallization conditions to produce that form consistently. We also control the particle size and residual solvent levels to minimize degradation. Our quality control laboratory verifies the crystal form and purity of every batch before release.
Packaging and storage are the final barriers between the Active Pharmaceutical Ingredients and the environment. The packaging must protect the API from moisture, light, and oxygen. The storage conditions must maintain the temperature and humidity within the specified range. The most common packaging materials are polyethylene bags, aluminum foil bags, and fiber drums. The choice of packaging depends on the sensitivity of the API. For moisture-sensitive products, a double polyethylene bag inside a fiber drum with a desiccant is often used. For light-sensitive products, an opaque or amber container is used. For oxidation-sensitive products, a nitrogen-flushed bag is used. The table below summarizes the packaging options and their protective properties.
| Packaging Material | Moisture Protection | Light Protection | Oxygen Protection | Typical Application |
| Polyethylene Bag | Moderate | None | Low | General purpose |
| Aluminum Foil Bag | High | High | High | Moisture and light sensitive |
| Fiber Drum | Moderate | High | Low | Bulk storage |
| Amber Glass Bottle | High | High | Low | Small quantity, light sensitive |
| Nitrogen-Flushed Bag | High | Depends on material | High | Oxidation sensitive |
At our factory, we select the packaging for each Active Pharmaceutical Ingredients based on its sensitivity profile. We use aluminum foil bags for moisture-sensitive products, amber bottles for light-sensitive products, and nitrogen-flushed bags for oxidation-sensitive products. We also provide our customers with recommended storage conditions, including temperature and humidity ranges, and we include desiccant packs in our shipments to maintain a dry environment during transit.
When sourcing Active Pharmaceutical Ingredients, buyers should request a complete stability data package from the supplier. This package should include the results of long-term, accelerated, and stress testing. Long-term testing is conducted at the recommended storage conditions and provides the data needed to assign the retest period or shelf life. Accelerated testing is conducted at elevated temperature and humidity and provides an indication of the product's sensitivity to environmental conditions. Stress testing is conducted under extreme conditions and provides information on the degradation pathways and the formation of degradation products. The table below summarizes the stability data that should be requested.
| Data Type | Conditions | Purpose |
| Long-Term | 25°C/60% RH or 30°C/65% RH | Assign retest period or shelf life |
| Accelerated | 40°C/75% RH | Assess sensitivity to temperature and humidity |
| Stress | Acid, base, oxidation, light, heat | Identify degradation pathways and products |
| Photostability | ICH Q1B conditions | Assess light sensitivity |
| Batch Analysis | Multiple batches | Confirm consistency of stability performance |
At Henan Purui Pharmaceutical Co., Ltd., we provide a complete stability data package with every Active Pharmaceutical Ingredients we supply. Our data package includes long-term, accelerated, and stress testing results, as well as photostability data where applicable. We also provide batch analysis data to demonstrate that our stability performance is consistent from batch to batch. Our goal is to give our customers the data they need to assign a reliable retest period and to design a formulation and packaging system that protects the API.
Evaluating an Active Pharmaceutical Ingredients supplier for stability requires a focus on the supplier's quality system, manufacturing control, stability program, and technical support. The supplier must have a robust quality system that ensures consistent production and thorough testing. They must control the manufacturing process to produce a consistent crystal form, particle size, and impurity profile. They must have a stability program that monitors the stability of each product over time. And they must provide technical support to help customers interpret the stability data and design a stable formulation. The table below summarizes the evaluation criteria.
| Evaluation Criterion | What to Look For | Why It Matters |
| Quality System | ISO 9001, GMP certification | Ensures consistent production and testing |
| Manufacturing Control | Crystal form control, particle size control | Ensures consistent stability performance |
| Stability Program | Ongoing stability studies, data trending | Confirms stability over time |
| Technical Support | Stability data interpretation, formulation support | Helps customers design stable products |
| Documentation | Complete stability data package | Supports regulatory submissions |
At our factory, we have a robust quality system that is certified to ISO 9001 and compliant with GMP requirements. We control the manufacturing process to produce consistent crystal form, particle size, and impurity profile. We maintain a comprehensive stability program that monitors the stability of every product we manufacture. And we provide technical support to help our customers interpret the data and design stable formulations. We invite you to evaluate us against these criteria and to consider us as your partner for Active Pharmaceutical Ingredients.
The following table provides the key product parameters for our Active Pharmaceutical Ingredients. These products are manufactured to meet the stability requirements of the pharmaceutical industry. Our factory can also produce custom APIs to meet specific requirements.
| Parameter | Specification Range | Notes |
| Purity | 98.0% - 99.9% | Depends on product |
| Crystal Form | Controlled polymorph | Most stable form selected |
| Particle Size | D50: 10 - 100 µm | Customizable for formulation |
| Residual Solvents | < 0.5% | ICH Q3C compliant |
| Heavy Metals | < 10 ppm | ICH Q3D compliant |
| Water Content | < 0.5% | Karl Fischer method |
| Packaging | PE bag, aluminum foil bag, fiber drum | Selected for sensitivity |
| Storage Conditions | 2-8°C or 15-25°C | Depends on product |
| Retest Period | 24 - 60 months | Based on stability data |
| MOQ | 1 kg | Negotiable for large orders |
| Lead Time | 2 - 6 weeks | Depends on quantity and customization |
At our factory, we manufacture our Active Pharmaceutical Ingredients to meet these specifications and more. We can customize the purity, crystal form, particle size, and packaging to suit your specific requirements. Our quality control system includes inspection of raw materials, in-process inspection, and final inspection before shipment. Our goal is to provide our customers with high-quality Active Pharmaceutical Ingredients that meet their stability requirements.
Question 1: What is the most common degradation pathway for active pharmaceutical ingredients?
Answer: The most common degradation pathways are hydrolysis and oxidation. Hydrolysis occurs when the API reacts with water, typically at ester, amide, or lactam bonds. Oxidation occurs when the API reacts with oxygen, typically at double bonds, aromatic rings, or heteroatoms. The relative importance of each pathway depends on the molecular structure of the API and the environmental conditions. At Henan Purui Pharmaceutical Co., Ltd., we characterize the degradation pathways of each product and develop processes to minimize degradation.
Question 2: How does crystal form affect API stability?
Answer: Different crystal forms (polymorphs) of the same API can have different physical and chemical stability. One form may be more thermodynamically stable than another, and one form may be more resistant to moisture or light. The most stable form should be selected for development, and the manufacturing process must be controlled to produce that form consistently. Our factory characterizes the polymorphic forms of each product and controls the crystallization conditions to produce the most stable form.
Question 3: What stability data should I request from an API supplier?
Answer: You should request long-term, accelerated, and stress testing data. Long-term data provides the basis for the retest period or shelf life. Accelerated data shows the sensitivity of the API to temperature and humidity. Stress data identifies the degradation pathways and products. You should also request photostability data if the API is light-sensitive, and batch analysis data to confirm consistency. At Henan Purui Pharmaceutical Co., Ltd., we provide a complete stability data package with every API we supply.
Question 4: How does packaging affect API stability?
Answer: Packaging protects the API from moisture, light, and oxygen. The choice of packaging depends on the sensitivity of the API. For moisture-sensitive products, a double polyethylene bag inside a fiber drum with a desiccant is often used. For light-sensitive products, an opaque or amber container is used. For oxidation-sensitive products, a nitrogen-flushed bag is used. Our factory selects the packaging for each API based on its sensitivity profile and provides recommended storage conditions.
Question 5: What should I do if an API fails stability testing?
Answer: If an API fails stability testing, the first step is to identify the degradation pathway and the cause of the failure. This may involve reviewing the manufacturing process, the packaging, and the storage conditions. The supplier should be able to provide technical support to investigate the failure and recommend corrective actions. At Henan Purui Pharmaceutical Co., Ltd., we work with our customers to investigate stability failures and to develop solutions that improve the stability of the API.
The stability of Active Pharmaceutical Ingredients is determined by a combination of intrinsic molecular factors, environmental conditions, manufacturing process, and packaging. By understanding these factors and selecting a supplier who controls them, buyers can ensure that the API remains stable throughout its shelf life. At Henan Purui Pharmaceutical Co., Ltd., our factory has the expertise and the systems to produce stable Active Pharmaceutical Ingredients. We characterize the degradation pathways of each product, control the manufacturing process to produce the most stable crystal form, and provide a complete stability data package to our customers. We also provide technical support to help our customers design stable formulations and packaging systems.
Whether you are sourcing a new API for a generic formulation, evaluating a second source for an existing product, or investigating a stability failure, we invite you to contact us to discuss your requirements. We can provide samples, stability data, and technical support. Our commitment to quality and customer satisfaction has made us a trusted partner for pharmaceutical companies around the world.
Contact Henan Purui Pharmaceutical Co., Ltd. today to discuss your Active Pharmaceutical Ingredients requirements and discover how our products can meet your stability needs.
